제목	2021년 4월 1일 생물정보학 세미나
작성자	관리자	작성일	2021-03-22
서울대학교 생물정보학 협동과정 주최로 세미나를 아래와 같이 열고자 하오니 많은 참여 바랍니다. 세미나는 Zoom을 통한 온라인 강의로 예정되어 있으며 강의에 참여하고자 하시는 분께서는 아래의 링크로 참여 부탁드리겠습니다.　 일시: 2021년 4월 1일　목요일 오전 11시 연사: 지요셉 연사님　(HEM) Zoom link:　https://snu-ac-kr.zoom.us/j/82315708212 Title:　An in-vitro screening system for developing personalized probiotics based on the gut microbiota Abstract The beneficial role of probiotics in our body and the underlying mechanisms have become a major focus in recent research. There is now general agreement that the impact of a probiotic strain is related to the modulation of the gut microbiota. It is known that probiotics can restore and rebalance the disrupted intestinal microbiota, resulting from a westernized diet and abuse of antibiotics. However, the efficacy of probiotics is not only strain-specific but also differs from person to person. Humans have individual and unique gut microbiota, specific for each person. The composition of the gut microbiome may also indicate certain underlying diseases or might be disrupted by particular infections. Differences in intestinal microbiota may explain the unpredictable activity of a probiotic strain. Even for the same person, one particular probiotic strain may show diverse effects depending on the condition or status of his gut microbiota. Therefore, consumption of probiotics, which is expected to regulate intestinal microbiota, also needs to be developed regarding the gut microbiota of each individual. We developed and patented a quick and simple in-vitro screening system called PMAS (Pharmaceutical Meta-Analysis Screening) that uses an individual’s fecal sample. First, various probiotic candidate strains were separately treated with different samples of feces and anaerobically cultured. For each treatment, the analysis of gut microbiota and its metabolites is performed through next-generation sequencing and by gas chromatography and/or other bioanalytical methods. By comparing and analyzing the results of the experimental groups treated with the specific candidate probiotic strains different from the control without any treatment, it is possible to determine the most ideal probiotic strain based on each person's fecal sample.　 Considering the complexity of the human microbiome and its diverse interactions with the human host, we realize that more research is needed on various aspects in order to link information from clinical trials with outcomes obtained by the PMAS system. By this, the in-vitro screening system has the potential to be used for developing personalized medicine based on the careful selection of functional probiotic strains.